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Highlights  
 
 Monocyte-derived TAM gradually replace resident peritoneal macrophages in 
metastatic ovarian cancer 
 Ovarian cancer cells promote membrane-cholesterol efflux in TAM 
 Cholesterol-efflux depletes lipid rafts and increases IL-4 signaling in TAM 
 Inhibition of ABC transporters reverts the tumor-promoting functions of TAM in 
ovarian cancer 
 
 
eTOC blurb 
 
Goossens et al. show that cancer cells scavenge membrane cholesterol from macrophages in 
tumors which reprogrammes them towards an immune-suppressive and tumor-promoting 
phenotype and makes them resistant to activation by anti-tumor cytokines.  
 
 
Summary 
 
Tumor-associated macrophages (TAM) have been shown to have important roles in the 
malignant progression of various cancers. However, macrophages also posses intrinsic 
tumoricidal activity, but rapidly adopt an alternative phenotype within tumors associated with 
immune-suppression and trophic functions supporting tumor growth. The mechanisms that 
promote TAM polarization remain poorly understood, these mechanisms may represent 
important therapeutic targets to block the tumor-promoting functions of TAM and restore their 
anti-tumor potential. Here we have characterized TAM in a mouse model of metastatic ovarian 
cancer. We show that ovarian cancer cells promote membrane-cholesterol efflux and depletion 
of lipid rafts from macrophages. Increased cholesterol efflux promoted IL-4 mediated 
reprogramming while inhibiting IFN-induced gene expression. These studies reveal an 
unexpected role for membrane-cholesterol efflux in driving the tumor-promoting functions of 
TAM, while rendering them refractory to pro-inflammatory stimuli. Thus, preventing cholesterol 
efflux in TAM may represent a novel therapeutic strategy to block pro-tumor functions and 
restore anti-tumor immunity.  
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Introduction 
 
There is now a wealth of clinical and experimental evidence that strongly links tumor-
associated macrophages (TAM) with tumor progression, invasion and metastasis (Noy and 
Pollard, 2014). In the vast majority of published studies, increased numbers of TAM correlate 
with poor prognosis, but in some cases, specific TAM subsets have been associated with 
beneficial outcomes (de Vos van Steenwijk et al., 2013; Ino et al., 2013). Indeed, macrophages 
have been shown to posses intrinsic tumoricidal activity and promote the activation of cytotoxic 
lymphocytes (Bonnotte et al., 2001; Hagemann et al., 2008; Mytar et al., 1999), but they rapidly 
adopt an alternative phenotype within tumors, associated with immune-suppression and 
trophic functions that support tumor growth (Mantovani et al., 2008). However, the 
mechanisms that promote TAM reprogramming in the tumor-microenvironment remain poorly 
understood. 
In mammals, macrophages are found in all tissues after birth and are endowed with trophic 
functions that contribute to organ development and remodelling (Pollard, 2009). Recent 
advances in genetic fate-mapping techniques have revealed that the majority of tissue-resident 
macrophages, at least in steady-state, develop from embryonic precursors and are maintained 
by local proliferation with little input from hematopoeitc stem cells (HSC) in the bone marrow 
(Schulz et al., 2012). Subsequent studies have shown that embryonic macrophages can be 
gradually replaced by HSC-derived blood monocytes, to varying degrees depending on the 
specific context (Ginhoux and Guilliams, 2016). But the functional implications of these distinct 
developmental origins and certainly their respective contributions to tumor progression remain 
unclear. In a recent study, both tissue-resident macrophages of embryonic origin and 
monocyte-derived TAM were shown to contribute towards tumor growth in a mouse model of 
pancreatic cancer (Zhu et al., 2017).  
The phenotype of tissue-resident macrophages is dictated by the tissue-specific signals in their 
respective niche (Gosselin et al., 2014; Lavin et al., 2014). However, during inflammation or 
tissue stress, monocyte-derived macrophages can be recruited into tissues and their functional 
reprogramming is dictated by the pathological context. It is now widely appreciated that 
macrophages follow a multi-dimensional model of activation states with distinct phenotypic and 
functional properties in response to different stimuli in the tissue microenvironment and can 
maintain considerable plasticity (Murray et al., 2014; Xue et al., 2014). Along these lines, TAM 
in various experimental models and human cancers have been shown to express uniques sets 
of gene patterns including the production of specific chemokines, cytokines and growth factors 
linked with tumor progression, such as CCL2, TNF, VEGF, basic fibroblast growth factor 
(bFGF) and matrix metalloproteinases (MMPs) (Kratochvill et al., 2015). Nevertheless, TAM 
are invariably reprogrammed towards a functional state that supports tumor growth and 
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immune-suppression and away from inflammatory phenotypes that could be associated with 
anti-tumor functions. The specific mechanisms that drive TAM accumulation and polarization 
in different tumors remain unclear. Several studies have shown that TAM are CSF-1 
dependent, as are most tissue macrophages, and CSF-1 signaling has been suggested to be 
an important factor in their reprogramming towards pro-tumor functions (Martinez et al., 2006; 
Noy and Pollard, 2014). CSF-1 and IL-4 signaling in TAM was later shown to cooperatively 
promote growth of lung metastatses in the MMTV-pyMT mouse model of mammary 
carcinonogenesis (DeNardo et al., 2009). However, although primary tumor-development in 
this model was CSF-1 dependent (Lin et al., 2006), IL-4 signaling in TAM did not impact 
primary tumors (DeNardo et al., 2009). Subsequent studies showed that the development of 
lung metastases, but not primary tumors, in the same model critically requires the recruitment 
of CCR2-dependent monocytes (Qian et al., 2011). Suggesting that IL-4 signaling, specifically 
in monocyte-derived TAM, promotes metastatic disease in this model. 
 
Here we have characterized TAM in a mouse model of metastatic ovarian cancer. We show 
that monocyte-derived TAM gradually replaced resident macrophages in this model and 
displayed an upregulation of cholesterol metabolism and reverse cholesterol efflux pathways 
during tumor progression. Further experiments revealed that ovarian cancer cells actively 
promoted plasma membrane cholesterol efflux from macrophages and the subsequent loss of 
cholesterol-rich membrane microdomains, or so called “lipid rafts”. Increased cholesterol efflux 
promoted enhanced IL-4 signaling in macrophages while inhibiting IFN-induced gene 
expression. IL-4 induced gene expression in TAM is associated with tumor-promoting 
functions, including increased arginine metabolism promoting immune-suppression and 
trophic functions, supporting invasion and metastasis. Whereas, IFN induced gene 
expression in TAM drives anti-tumor functions. We further demonstrate that IL-4 signaling and 
cholesterol efflux pathways in TAM significantly contribute to tumor progression in vivo. These 
studies suggest an important role for membrane-cholesterol efflux in driving IL-4 signaling and 
tumor-promoting functions of TAM in ovarian cancer, while rendering them refractory to 
reprogramming by anti-tumor cytokines. Therefore, preventing cholesterol efflux in TAM could 
represent a novel therapeutic strategy to block pro-tumor functions and restore anti-tumor 
immunity.  
 
 
Results 
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Origins of TAM during ID8 tumor development. 
High grade serous ovarian cancer (HGSC) is frequently associated with colonisation of the 
peritoneal cavity by cancer cells (George et al., 2016). ID8 cells are spontaneously transformed 
mouse ovarian surface epithelial cells (Urzua et al., 2016), when adoptively transferred by 
intra-peritoneal (i.p.) injection in syngeneic mice, these cells progressively develop a malignant 
ascites with tumor nodules throughout the peritoneal cavity (Hagemann et al., 2008), which is 
characteristic of HGSC. The peritoneal cavity is populated by two major subsets of serosal 
macrophages; large peritoneal macrophages (LPM), which are most abundant, and a minor 
population of small peritoneal macrophages (SPM) (Ghosn et al., 2010). Previous studies have 
shown that SPM and LPM have distinct developmental origins; SPM develop from blood 
monocytes which are derived from bone marrow progenitors, whereas LPM are derived from 
embryonic progenitors and are maintained independently of blood monocytes, retaining 
proliferative capacity for self-renewal (Yona et al., 2013). More recent studies have shown that 
LPM can be progressively replaced by long-lived bone marrow-derived macrophages that 
maintain self-renewal potential (Bain et al., 2016). To monitor the dynamics of peritoneal 
macrophages (PM) during ID8 tumor growth, we first characterized macrophage subsets by 
flow cytometry. SPM and LPM can be distinguished by F4/80 and MHCII expression; SPM are 
MHCIIhi F4/80lo whereas LPM are F4/80hi MHCIIlo (Fig.1A). LPM represent approximately 80 
% of PM in naïve mice, however, after seeding of ID8 cells in the peritoneal cavity, a significant 
population of F4/80int MHCIIint PM rapidly accumulates (intPM; Fig.1A). Kinetic analysis of total 
cell numbers revealed that LPM numbers remain relatively constant throughout tumor 
progression, while intPM progressively accumulate and eventually become the dominant TAM 
population (Fig.1B). 
 
To determine the dynamics of PM subsets during ID8 tumor growth, we performed fate-
mapping studies with shielded radiation chimera mice. Radiation chimeras can be used to 
determine the contribution of bone marrow-derived progenitors towards cells in a given tissue. 
However, irradiation kills tissue-resident macrophages that then become replaced by 
monocyte-derived cells, thus to distinguish tissue-resident cells from monocyte-derived 
macrophages from the bone marrow, it is necessary to protect the tissue from the effects of 
radiation using lead shielding. To study the origins of PM subsets during ID8 tumor growth, we 
shielded the abdomen of host C57BL6 CD45.1 congenic mice during irradiation and then 
adoptively transferred a mixture of bone marrow cells from mice expressing both CD45.1 and 
CD45.2 (CD45.1/2) and Ccr2-/- mice, expressing only CD45.2. This allowed the distinction 
between host (CD45.1) and donor cells (CD45.1/2 or CD45.2), as well as their CCR2-
dependency, CD45.2 single-positive cells being CCR2-dependent. Due to the low engraftment 
efficiency of Ccr2-/- bone marrow cells, Ccr2-/- donor cells were mixed at a ratio of 4:1 with 
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competitor B6.CD45.1/2 cells. Five weeks after bone marrow engraftment, chimeric mice were 
injected with ID8 cells to track the contribution of bone marrow-derived cells to PM subsets 
(Fig.1C). CD45.1 and CD45.2 expression in TAM subsets was measured by flow cytometry a 
further 8 weeks after injection of ID8 cells, a total of 13 weeks after adoptive transfer of bone 
marrow cells, chimerism was normalised to blood monocytes. These experiments revealed 
that SPM and intPM were derived from CCR2-dependent bone marrow progenitors, with 
almost 100 % chimerism after 8 weeks of tumor growth (Fig.1D,E). However, at this time point, 
LPM only showed approximately 30 % chimerism, implying that LPM are more gradually 
replaced by bone marrow-derived cells during tumor development. To confirm the CCR2-
dependency of intPM, we analyzed the accumulation of PM subsets in full CCR2 deficient mice 
(Ccr2-/-), as expected, both SPM and intPM were drastically reduced in Ccr2-/- mice bearing 
ID8 tumors, whereas CCR2 deficiency had little impact on LPM numbers (Fig.S1).  
To confirm the continuous contribution of blood monocytes to SPM and intPM populations 
throughout tumor growth, we used a fluorescent fate-mapping approach. The chemokine 
receptor Cx3cr1 is expressed by blood monocytes (Geissmann et al., 2003) and previous 
studies have demonstrated the fate-mapping of monocyte-derived cells using knock-in mice 
that express a tamoxifen-inducible Cre-recombinase from the Cx3cr1 locus (Cx3cr1CreER), 
crossed to mice expressing a ubiquitous lox-STOP-lox reporter cassette (Yona et al., 2013). 
As expected, we did not detect Cx3cr1 expression in steady-state LPM using the Cx3cr1egfp/+ 
reporter mice, however, high levels of Cx3cr1 expression were observed in SPM and 
intermediated levels in intPM (Fig.S1), reflecting the likely monocyte origins of these cells. We 
crossed Cx3cr1CreER mice with Rosa26-lsl-tdRFP reporter mice (Cx3cr1CreER:R26-tdRFP) and 
injected these mice with ID8 cells to track monocyte-derived cells during tumor growth. Six 
weeks after injection of ID8 cells, mice were given a single dose of 4-OHT by oral gavage (p.o.) 
and RFP expression in TAM subsets was measured by flow cytometry ten days later. These 
experiments showed strong RFP labelling in SPM and intPM within 10 days of 4-OHT 
administration, with very little labelling of LPM (Fig.1F,G). These data clearly demonstrated the 
contribution of blood monocytes to SPM and intPM during tumor growth, even within this short 
time frame. 
 
Transcriptional profiling of TAM. 
To evaluate the impact of the tumor-microenvironment on PM phenotype, we performed global 
gene expression analysis using microarrays on bulk PM from naïve mice and at different time 
points during tumor progression. We isolated naïve F4/80hi PM and TAM at 5, 12 and 21 days 
during ID8 tumor development by flow cytometry (Fig.S2). Total RNA was extracted and 
samples were analyzed using MoGene 1.0st microarrays. RMA normalised data were filtered 
and analyzed for variations in gene expression. The heatmap in figure S2B shows the 1000 
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most variable genes in the dataset. To extract differentially expressed genes (DEGs) between 
naïve PM and TAM at the different time points, we used Anova with an adjusted p value and 
a threshold of 1.5 fold change (FC). We then used Gene Ontology (GO) enrichment analysis 
to identify pathways affected in TAM at different time points (Fig.1H,I). DEGs are represented 
by edges (green = up; blue = down) and individual GO terms are represented by nodes. GO 
terms that are similar, as indicated by the intersection of DEGs in a given GO term, are closer 
to each other. This generates clusters of similar GO terms indicating common biological 
processes within the cluster. This analysis revealed a major cluster of upregulated genes 
related to immunity in TAM after 5 days (Fig.1H), possibly reflecting a tumoricidal response 
triggered by resident PM in response to ID8 cells. However, after 21 days, when tumors had 
become more established, the gene expression profile of TAM more closely resembled the 
phenotype of naïve PM (Fig.S2). At this later time point, there was an upregulation of distinct 
gene clusters, including a large cluster of genes related to the innate immune response and 
tumor necrosis factor (TNF) signaling, in keeping with previous data showing an important role 
for TNF in this model (Charles et al., 2009; Hagemann et al., 2006), and also a distinctive 
cluster of genes associated with cholesterol metabolism and efflux (Fig.1I). To confirm the 
enrichment of genes related to cholesterol homeostasis, we merged several published 
genesets (Rayner et al., 2011) and known hallmarks to generate an extended gene list 
representing cholesterol homeostasis. This compiled geneset also showed a significant 
enrichment in TAM and among the up-regulated genes were known actors in cholesterol 
metabolism and efflux, including; Abcg1, Ldlr, Pparg, Hmgcs1, Hmgcr, Srebf2 (Fig.S2). 
 
Increased membrane cholesterol efflux in TAM. 
Changes in membrane cholesterol content have been shown to dramatically affect 
macrophage activation in response to pro-inflammatory stimuli, such as bacterial 
lipopolysaccharide (LPS) (Fessler and Parks, 2011). This is thought, at least in part, to be due 
to the depletion of cholesterol rich membrane micro-domains, also called lipid rafts, which act 
as signaling platforms for certain receptors. But membrane cholesterol influences multiple 
facets of membrane structure and dynamics that can also affect receptor signaling. To confirm 
the finding that cholesterol efflux pathways were upregulated in TAM, we sought to measure 
effects on cholesterol membrane content in TAM from ID8 tumor bearing mice. Cholesterol 
rich membrane micro-domains are commonly measured using cholera toxin B (CTB) staining, 
which binds to ganglioside GM1, the accumulation of which is linked with membrane 
cholesterol content. We isolated naïve PM and TAM at 5 and 21 days after injection of ID8 
cells, stained the cells with Alexa Fluor 488-conjugated CTB and analyzed them by confocal 
microscopy. We observed that CTB staining was similar in naïve PM and TAM isolated at 5 
days, but was significantly decreased in TAM after 21 days of tumor growth (Fig.2A,B), 
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indicating that the tumor-microenvironment may promote the depletion of cholesterol rich 
membrane micro-domains in TAM, in accordance with the upregulation of genes regulating 
cholesterol efflux in these cells (Fig.1I). To test if ID8 tumor cells had a direct effect on 
macrophage cholesterol efflux, we co-cultured ID8 cells with bone marrow-derived 
macrophages (BMDM) in vitro. After just one hour of co-culture, there was a significant 
decrease of CTB staining in BMDM (Fig.2C,D), indicating tumor cells actively promoted the 
depletion of membrane cholesterol in macrophages. To test if factors secreted by tumor cells 
were responsible for this effect, we incubated BMDM with conditioned medium obtained from 
ID8 cell cultures (ID8-CM). This also resulted in a rapid reduction in CTB staining, that was 
almost equivalent to the effects of methyl--cyclodextrin (MCD), which extracts cholesterol 
from cell membranes (Ostrom and Liu, 2007) (Fig.2E,F). Although CTB is commonly used to 
measure cholesterol rich membrane micro-domains, this is a rather indirect measure of 
membrane cholesterol. Another method to asses membrane cholesterol content exploits the 
highly ordered structure of cholesterol-rich membrane microdomains by the use of phase-
sensitive fluorescent probes such as Laurdan and di-4-ANEPPDHQ (Owen et al., 2011; 
Sonnino and Prinetti, 2013). These molecules adapt their emission wavelength based on local 
membrane order, which is a direct reflection of cholesterol content, independently of 
membrane-associated proteins. To confirm our findings, we labelled macrophages with di-4-
ANEPPDHQ and found a significant decrease of membrane order in the presence of ID8-CM 
(Fig.2G,H). These assays confirmed that the reduction in CTB staining observed after ID8-CM 
treatment, correlated with alterations in membrane order that reflect reduced levels of 
membrane cholesterol. Furthermore, we measured total cholesterol levels in macrophages 
cultured in the presence or absence of tumor cell-conditioned medium and observed a 
significant decrease of total cellular cholesterol (Fig.2I). Finally, to directly measure cholesterol 
efflux from macrophages, we loaded BMDM with thymidine (3H)-labelled cholesterol and 
measured its efflux into the culture media after addition of the apolipoprotein A1 (ApoA1). 
Membrane cholesterol efflux is mediated by the transfer of cholesterol to lipoproteins through 
ABC transporters (Zhao et al., 2010), in the case of ApoA1 this occurs through the transporter 
ABCA1. These assays showed that addition of ID8-CM significantly increased cholesterol 
efflux from macrophages, which was reversed in BMDM from ABCA1-deficient mice (Abca1-/-
), demonstrating that this was due to an increased efflux of membrane cholesterol (Fig.2J).  
 
Tumor cell-derived hyaluronic acid (HA) drives cholesterol efflux in macrophages. 
The studies described above showed that ID8 cells increased cholesterol efflux from 
macrophages. This effect could be recapitulated with conditioned medium but not with fixed 
cells (Fig.3A), indicating that cholesterol efflux is promoted by a secreted factor. In order to 
further characterize this factor, we exposed ID8-CM to a series of treatments, including ultra-
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centrifugation, boiling (95oC for 5 min), repeated freeze/thaw cycles, DNAse and proteinase K, 
none of which had any impact on the ability of ID8-CM to deplete CTB staining in macrophages 
(data not shown). However, size fractionation of ID8-CM with cut-offs at 3, 10, 30 or 100 kDa, 
revealed that this activity was present in a fraction with a molecular weight above 100 kDa 
(Fig.3B). Several previous studies have shown that the extracellular matrix (ECM) component 
hyaluronic acid (HA) can be produced by tumor cells and has been linked with increased tumor 
progression (Chanmee et al., 2016). HA also forms high molecular weight oligomers (>100 
kDa) with distinct biological activity (Gomez-Aristizabal et al., 2016; Kolapalli et al., 2016; 
Rayahin et al., 2015). Furthermore, receptors for HA are expressed by TAM, namely CD44 
and Lyve-1 (Chanmee et al., 2016; Turley et al., 2002). To test the hypothesis that HA in ID8-
CM contributed to the effects on membrane cholesterol content, we treated ID8-CM with 
hyaluronidase (HAse) to degrade HA. Indeed, ID8-CM treated with HAse was no longer able 
to deplete CTB staining in macrophages (Fig.3C). Conversely, when HA of different molecular 
weights was added to macrophages in normal culture medium, we observed a reductiion of 
CTB staining with increasing molecular weight (Fig.3D). These experiments suggested that 
high molecular weight HA produced by ID8 cells promotes membrane cholesterol depletion in 
macrophages. Given that HA is an important component of ECM in many cancers, including 
EOC (Kolapalli et al., 2016), this suggests HA could affect the phenotype of TAM through 
membrane cholesterol depletion. 
 
Cholesterol efflux promotes IL-4 mediated macrophage reprogramming. 
Depletion of membrane cholesterol has been shown to profoundly affect macrophage 
activation in response to pro-inflammatory stimuli (Fessler and Parks, 2011; Pradel et al., 
2009), which suggests that cholesterol efflux in TAM could affect their programming by signals 
in the tumor-microenvironment. In some instances, TAM have been shown to exhibit a tumor-
promoting phenotype that can be driven by Th2 cytokines such as IL-4 or IL-13, and are 
skewed away from the pro-inflammatory and immunostimulatory activation state, for example 
induced by Th1 cytokines such as IFN(DeNardo et al., 2009; Murray et al., 2014). To test the 
effects of ID8 cells on macrophage reprogramming, we stimulated BMDM with IL-4 or IFN in 
the presence or absence of ID8-CM and measured the induction of IL-4 and IFNgene 
expression, respectively. ID8-CM pre-treatment profoundly increased the expression of IL-4 
induced genes; Arg1, Retnla, Chi3l3 and Mrc1 (Fig.4A). In contrast, ID8-CM inhibited the IFN 
induced expression of Nos2 and Il12b (Fig.4B), as well as other IFN-regulated genes including 
Cxcl9, Cxcl10 and Ciita (Fig.S3), demonstrating that ID8-CM promoted macrophage 
programming towards an IL-4 induced pro-tumor phenotype. Similar results were obtained 
after co-culture of ID8 cells with BMDM or with IL-13 treatment, which also signals through the 
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IL4 receptor alpha chain (IL4RA) (Fig.S3). These effects were restricted to the high molecular 
weight (>100 kDa) fraction of ID8-CM (Fig.S3) and were not sensitive to freeze/thaw cycles, 
boiling, ultracentrufugation, DNAse or proteinase K treatment (data not shown). 
To evaluate the effects of membrane cholesterol depletion on macrophage reprogramming we 
used several mechanistically distinct treatments to induce cholesterol efflux, in comparison 
with ID8-CM; 9-cis-retenoic acid (9cRA) upregulates expression of ABC transporters and 
thereby induces cholesterol efflux (Ricote et al., 2004), whereas high-density lipoprotein (HDL) 
and ApoA1 strip cholesterol directly from the cell membrane (Zhao et al., 2010). Treatment of 
BMDM with 9cRA, HDL or ApoA1 resulted in similar levels of reduction in CTB staining as 
seen upon ID8-CM treatment (Fig.4C), as well as increased IL-4 induced gene expression, 
while inhibiting IFN induced genes (Fig.4D). In contrast, the addition of exogenous cholesterol 
to BMDM, reduced the effects of ID8-CM on IL-4 induced Arg1 and IFN induced Nos2 
expression (Fig.S3).  
These data suggested that membrane cholesterol depletion promotes IL-4 mediated 
macrophage activation and abrogates IFN signalling. To directly test the role of cholesterol 
efflux in macrophage reprogramming by ID8-CM, we used BMDM from mice with a combined 
myeloid deficiency in the ABCA1 and ABCG1 reverse cholesterol efflux transporters 
(Abca1/g1Lyz2). Treatment with ID8-CM or other membrane cholesterol-depleting agents failed 
to reduce CTB staining in BMDM from Abca1/g1Lyz2 mice (Fig.4E), which indeed reversed the 
increase in IL-4 induced gene expression by ID8-CM and the inhibition of IFN induced genes 
(Fig.4F), indicating that membrane cholesterol efflux through ABCA1 and/or ABCG1 promoted 
IL-4 mediated macrophage activation in the presence of ID8-CM.  
 
Tumor-induced macrophage reprogramming is STAT6 and PI3K dependent. 
To further characterize the mechanisms behind increased IL-4 induced gene expression in the 
presence of ID8-CM and how this may relate to cholesterol efflux, we analyzed IL-4 receptor 
signaling pathways. First, we observed no increase in the expression levels of the IL-4 receptor 
(IL4RA) on macrophages treated with ID8-CM (data not shown), but immunofluorescent 
staining illustrated an increased intracellular clustering of the receptor that suggested 
endosomal accumulation, which previously has been shown to promote downstream signaling 
(Gandhi et al.; Kurgonaite et al.) (Fig S4). We therefore measured activation of signaling 
pathways downstream of the IL-4 receptor. IL-4 induced gene expression is regulated by JAK-
mediated phosphorylation of the STAT6 transcription factor. Treatment of BMDM with ID8-CM 
increased levels of activated STAT6 (pY-STAT6) in response to IL-4 (Fig.5A,D; Fig.S4) while 
reducing the accumulation of phosphorylated STAT1 (pY-STAT1), upon IFN activation 
(Fig.5B,E; Fig.S4). As expected, IL-4 induced gene expression in the presence of ID8-CM was 
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abolished in BMDM derived from STAT6 deficient mice (Stat6-/-) (Fig.S4). IL-4 signaling also 
activates PI3K, which was recently shown to be an important pathway for the tumor-promoting 
functions of TAM (Kaneda et al., 2016a; Kaneda et al., 2016b), furthermore, increased PI3K 
signaling has been shown to promote IL-4 induced gene expression in macrophages (Rauh et 
al., 2005). To assess PI3K activation we measured phosphorylation of the downstream kinase 
Akt/PKB. We observed a marked increase in serine 473 phosphorylation of Akt (pS-Akt) in the 
presence of ID8-CM (Fig.5C,F; Fig.S4), this correlated with increased accumulation of 
phosphatidylinositol (3,4,5)-triphosphate (PIP3), the product of PI3K activity, as measured by 
confocal microscopy (Fig.S4). To determine the contribution of PI3K to IL-4 mediated 
reprogramming in the presence of ID8-CM, we treated cells with the PI3K inhibitor LY294002. 
As expected, LY294002 treatment blocked the increase in pS-Akt by ID8-CM (Fig.5G) and 
also abrogated the increase in IL-4 induced Arg1 and Chi3l3 expression (Fig.5H,I; Fig.S4), 
indicating that PI3K activity was critical for ID8-CM induced reprogramming. To determine the 
role of cholesterol efflux in STAT6 and PI3K activation, we again treated macrophages with 
9cRA and ApoA1 to deplete membrane cholesterol, both treatments resulted in similar 
increases in the accumulation of pY-STAT6 and pS-Akt (Fig.5J,K). Furthermore, macrophages 
lacking the ABCA1 and ABCG1 cholesterol efflux transporters failed to increase pY-STAT6 
and pS-Akt upon treatement with ID8-CM (Fig.5L,M). In addition, increased pY-STAT6 and 
pS-Akt accumulation was restricted to the high molecular weight (>100 kDa) fraction of ID8-
CM and could be reversed by HAse treatment (Fig.S4), indicating that HA-mediated 
cholesterol efflux promoted increased STAT6 and Akt activation. 
The specific accumulation of pS-Akt in the presence of ID8-CM was intriguing, serine 473 
phosphorylation of Akt is mediated by mammalian target for rapamycin complex 2 (mTORC2) 
(Jacinto et al., 2006), which is activated by PI3K through PIP3 accumulation (Liu et al., 2015). 
Interestingly, mTORC2 was also recently shown to promote IL-4 induced macrophage 
activation in response to metabolic stress (Huang et al., 2016). Thus, we hypothesised that 
ID8-CM induced PIP3 accumulation could activate mTORC2-mediated pS-AKT 
phosphorylation and increase IL-4 induced gene expression. In the absence of any specific 
mTORC2 inhibitors, to test the role of the mTORC complex we used rapamycin, which blocks 
mTORC1, and Torin which blocks both mTORC1 and mTORC2. Rapamycin treatment only 
partially inhibited ID8-CM induced pS-Akt accumulation in macrophages, however, Torin 
treatment completely inhibited ID8-CM induced pS-Akt phosphorylation in a dose-dependent 
manner (Fig.5N,O), suggesting that mTORC2 activity is required for ID8-CM induced pS-Akt 
accumulation in macrophages. 
In summary, IL-4 induced macrophage activation or reprogramming in response to ID8-CM 
requires PI3K-mTORC2-Akt activity and is driven by STAT6.   
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IL-4 induced STAT6 and PI3K signaling in TAM drives tumor progression in EOC. 
To test the relevance of these pathways for TAM and tumor progression in vivo, we revisited 
our characterisation of TAM in ID8 tumors. Our conclusions from the data presented in figure 
1, was that monocyte-derived TAM gradually replaced resident macrophages during tumor 
progression and that TAM showed an enrichment for cholesterol efflux pathways (Fig.1I). 
However, these analyzes were performed on bulk TAM populations, including resident PM and 
monocyte-derived TAM. To refine our analysis and determine the specific gene expression 
signature of monocyte-derived cells, we isolated F4/80lo CCR2+ monocytes (MN), alongside 
F4/80hi LPM, which were further divided into Tim4+ and Tim4- subsets (Fig.S5). Tim4 was 
previously shown to be a marker for proliferative, self-renewing LPM (Rosas et al., 2014), 
whereas Tim4- F4/80hi cells represent monocyte-derived LPM, which are CCR2-dependent 
(Fig.1; Fig.S5). First, we collected these 3 populations from naïve mice and at different time 
points during tumor progression for microarray analysis. We performed a pairwise comparison 
between the 3 populations in naïve mice and extracted a specific gene signature for each 
subset, applying a 1.5 FC threshold and a p-value of 0.05. Using the Minimal method 
(pairwise[Mean(test)/Mean(ref)]), we identified sets of 553 genes specific for MN, 131 for Tim4+ 
PM and 84 for Tim4- PM (Table S1). Given that CCR2 was the highest DEG between Tim4- 
and Tim4+ populations, this strongly supported the monocytic origin of Tim4- cells, in keeping 
with our previous analysis (Fig.S5). We then used these gene sets to perform enrichment 
analysis (GSEA) with DEGs from the equivalent 3 subsets in ID8 tumor-bearing mice. This 
analysis showed a significant down-regulation of the naïve Tim4+ PM gene signature and a 
strong enrichment of the MN and Tim4- gene signatures in Tim4+ TAM (Fig.6A), supporting our 
conclusion that the tumor-microenvironment promotes the replacement of resident PM with 
MN-derived cells that acquire a resident-like phenotype, including expression of Tim4 (Fig.1; 
Fig.S5). To determine the specific genes associated with this phenotype, we extracted the 
leading edges (LEs) for this enrichment, that is the genes most strongly associated with the 
enrichment of the MN gene signature in Tim4+ TAM. We identified 173 LEs that were enriched 
at all time points in Tim4+ TAM (Fig.6B; Table S2), which we then used for Ingenuity Pathway 
Analysis (IPA). The most significant pathway associated with these genes was the IL-4 
pathway (Fig.6B), suggesting that IL-4 in the tumor-microenvironment could be an important 
upstream regulator for the development of the monocyte-derived TAM phenotype.   
 
To confirm the role of IL-4 signaling in tumor progression in vivo, we treated ID8 tumor-bearing 
mice with an IL-4 receptor blocking monoclonal antibody (IL4ra) and monitored tumor 
progression. Treatment with IL4ra significantly reduced ID8 tumor growth in vivo (Fig.6C), 
suggesting that IL-4 signaling is an important factor for tumor progression in this model. 
Furthermore, chimeric mice with hematopoietic deficiency in STAT6 (Stat6-/-) or PI3K (Pik3cd-
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/-), also showed significantly reduced tumor growth (Fig.6D,E), indicating that both signaling 
pathways in tumor stromal cells are important factors for tumor progression. To evaluate the 
impact of these pathways on TAM phenotype in vivo, we sorted bulk TAM from Pik3cd-/- 
chimeric mice by flow cytometry and isolated RNA for microarray analysis. Expression of Arg1, 
Il10, Ccl2 and Stab1, which have previsouly been shown to upregulated in TAM, were 
significantly downregulated in macrophages from Pik3cd-/- chimeric mice compared to controls 
(Fig.S5), suggesting that PI3K activation contributes to the TAM phenotype. To further analyze 
the impact of PI3K activation on TAM, we generated a gene set from all DEGs between naïve 
PM and TAM from wild-type mice. Subsequent GSEA showed a significant enrichment for 
genes expressed by naïve PM in Pik3cd-/- cells (Fig.6F), confirming that PI3K activity 
contributes to the promotion of the TAM phenotype. In addition, there was no enrichment of 
genes associated with the IL-4 dependent TAM phenotype (Fig.6G), described above (Fig.6B; 
Table S2). These data Indicated that PI3K is an important regulator of this gene set in TAM. 
Interestingly, using an established gene set for tumoricidal phenotype (GSE26912), which was 
enriched in naïve PM compared to TAM, we also observed an enrichment in Pik3cd-/- TAM 
compared to wild-type cells, suggesting that these cells retained a more tumoricidal phenotype 
in the absence of PI3K activation (Fig.S5). Finally, to evaluate the role of cholesterol efflux in 
TAM in vivo, we established ID8 tumors in mice with a myeloid-specific deletion of both ABCA1 
and ABCG1 (Abca1/g1Lyz2). ID8 tumor progression was significantly impaired in Abca1/g1Lyz2 
mice compared to littermate controls (Fig.6H). Furthermore, microarray analysis of TAM sorted 
from these mice showed a significant downregulation of genes associated with the IL-4 
dependent TAM phenotype and a positive enrichment for tumoricidal genes (Fig.6I; Fig.S5), 
reflecting the phenotype of PI3K deficient TAM. 
Collectively, these data showed that IL-4 signaling in TAM plays an important role in tumor 
progression in this model. Furthermore, the PI3K pathway and increased cholesterol efflux, 
contribute significantly to the functional polarization of TAM and tumor progression in vivo.  
 
 
Discussion 
 
It is now well appreciated that tumor-associated macrophages (TAM) can play an important 
role in cancer progression. TAM contribute to tumor progression by various mechanisms, 
including immune-suppression and trophic functions, supporting angiogenesis, cell 
proliferation, invasion and metastasis. For example, increased expression of arginase I (Arg1) 
in TAM, depletes arginine which is required by activated T cells and consequently increases 
polyamine synthesis, which supports cancer cell proliferation. However, macrophages also 
posses intrinsic anti-tumor potential, through direct tumoricidal functions and orchestrating 
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anti-tumor immunity, which may be particularly relevant in response to therapy (Bonnotte et 
al., 2001; Hagemann et al., 2008; Mytar et al., 1999). But the mechanisms by which TAM 
become polarized towards pro-tumor functions remain poorly understood.  
Here we have studied TAM in a mouse model of epithelial ovarian cancer (EOC), that reflects 
the peritoneal spread of high-grade serous ovarian cancer (HGSC). In mice, the peritoneal 
cavity contains a major resident macrophage population of embryonic origin (large peritoneal 
macrophages; LPM), as well as a minor population of monocyte (MN)-derived macrophages 
(small peritoneal macrophages; SPM). During tumor progression we showed that MN-derived 
TAM accumulate and gradually replace resident macrophages in the peritoneal cavity. We 
then analyzed the global changes in gene expression in TAM over time using microarrays and 
used pathway analysis to reveal changes in gene expression linked with different pathways 
and biological functions. At early time points, TAM displayed a more pro-inflammatory gene 
signature, which strongly distinguished them from naïve resident PM. However, in established 
tumors, TAM acquired a phenotype more closely resembling resident PM, which suggested a 
dynamic reprogramming of TAM phenotype during tumor progression.  
Among the pathways upregulated in TAM from established tumors compared to naïve PM was 
a cluster of genes related to cholesterol metabolism and reverse cholesterol efflux. Reverse 
cholesterol efflux in macrophages is regulated by membrane cholesterol efflux transporters, 
such as ABCA1 and ABCG1. These transporters regulate the levels of cholesterol in the 
plasma membrane, which has a profound influence on macrophage responses to extracellular 
stimuli. For example, ABCA1 deficient macrophages accumulate cholesterol in the membrane 
and are hyperresponsive to pro-inflammatory stimuli, such as bacterial lipopolysaccharide 
(LPS) (Fessler and Parks, 2011; Pradel et al., 2009). This is thought to be due to the increase 
in cholesterol-rich membrane microdomains, also called lipid rafts, which are required to 
promote TLR4-signaling. However, previous studies have also shown that ABCA1-deficient 
macrophages are hyporesponsive to other stimuli, including IL-4 and IL-13 (Pradel et al., 
2009). Interestingly, ABCG1 deficiency in macrophages was shown to increase their pro-
inflammatory phenotype and reduce growth of subcutaneous tumors in mice fed on a high-fat 
diet (Sag et al., 2015), suggesting that cholesterol accumulation in tumor-associated 
macrophages can abrogate their pro-tumor functions.  
Here, we showed that ovarian cancer cells actively promoted membrane cholesterol efflux in 
macrophages, which was associated with increased IL-4 signaling and inhibition of IFN-
induced gene expression, resulting in transcriptional and functional reprogramming of TAM. 
Depletion of membrane cholesterol in macrophages increased PI3K activity and mTORC2-
mediated Akt phosphorylation. Both PI3K and mTORC2 have previously been linked with IL-4 
mediated macrophage activation in different contexts (Huang et al., 2016; Rauh et al., 2005). 
Furthermore, PI3K was recently shown to be a critical pathway to maintain the pro-tumor 
 15 
functions of TAM (Kaneda et al., 2016a; Kaneda et al., 2016b). The exact mechanism by which 
membrane cholesterol regulates PI3K/mTORC2 activation remains to be elucidated. Perhaps 
cholesterol-rich membrane microdomains are required to recruit negative regulators of PI3K 
activity, such as the lipid phosphatase SHIP-1. Previous studies have suggested that SHIP 
may reside in detergent-resistant membrane fractions (Galandrini et al., 2002) and SHIP-1 is 
known to inhibit IL-4 signaling in macrophages (Rauh et al., 2005).  
The distinct metabolic environment of tumors has long been suggested to influence the 
phenotype of tumor-infiltrating immune cells, rendering them hyporesponsive and contributing 
to immune-suppression. Cancer cells rely heavily on cholesterol, which they can scavenge 
from the tumor-microenvironement through upregulation of apolipoproteins and their receptors 
(Guillaumond et al., 2015; Podzielinski et al., 2013; Villa et al., 2016). This may lead to 
cholesterol depletion in tumor-stromal cells, and particularly TAM which express high levels of 
the ABCA1 and ABCG1 efflux transporters. Our in vitro studies suggest hyaluronic acid (HA) 
could be an important factor produced by cancer cells that promotes this process. HA is a 
major component of the extracellular matrix (ECM) in many human cancers, including ovarian 
cancer and in many cases the degree of HA accumulation strongly correlates with poor 
prognosis (Kolapalli et al., 2016; Sironen et al., 2011). Macrophages express at least two 
distinct receptors for HA; CD44 and Lyve1. Interestingly, CD44 signaling has previously been 
associated with PI3K activation in TAM (Lenart et al., 2017). Co-incidentally, PI3K also 
upregulates ABCA1 expression in macrophages (Chen et al., 2012; Okoro et al., 2016), 
potentially creating a feed-forward loop for enhanced cholesterol efflux and IL-4 mediated 
reprogramming.   
 
In summary, we describe an important role for membrane cholesterol efflux in the regulation 
of macrophage activation state in the tumor-microenvironment. Depletion of membrane 
cholesterol renders macrophages hyperresponsive to pro-tumor signals, such as IL-4, but 
refractory to activation by the anti-tumor cytokine IFN. We propose that cholesterol efflux 
pathways may represent novel targets to abrogate the pro-tumor functions of TAM while 
retaining potentially beneficial anti-tumor effects in response to therapy.  
  
Limitations of this study 
Despite functional data demonstrating the contribution of IL-4 signaling to tumor progression 
in this model, IL-4 was not detectable in ascites from tumor-bearing mice, indicating this 
cytokine is produced at very low levels and consumed rapidly. This illustrates the significance 
of enhanced sensitivity of TAM to IL-4, which is increased by several orders of magnitude due 
to membrane cholesterol depletion. These studies are likely to be relevant to human ovarian 
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cancer, where IL-4 expression has been associated with poor clinical outcome (Candido et al.; 
Clendenen et al.; Munster et al., 1998). The source of IL-4 in this context remains unknown. 
While other cancer cells, including prostate, breast and bladder, have been shown to express 
IL-4 (Conticello et al., 2004), conditioned medium from ID8 cells alone was not sufficient to 
activate IL-4 signaling in macrophages. Other potential sources of IL-4 include CD4 T cells 
(DeNardo et al., 2009), eosinophils (Kratochvill et al., 2015), innate lymphocytes or 
macrophages themselves.  
The precise mechanism by which the activity of ABC transporters is upregulated in TAM also 
remains to be elucidated. Cholesterol efflux was rapidly induced upon exposure to tumor-cell 
conditioned medium and no increase in Abca1 or Abcg1 mRNA was observed (data not 
shown), suggesting a post-transcriptional mechanism. However, cholesterol efflux was 
dependent PI3K activation associated with increased Akt serine 473 phosphorylation. Other 
studies have shown serine 473 phosphorylation of Akt regulates the translocation of ABC 
transporters to the plasma membrane (Huang et al.). This may offer a mechanistic explanation 
for increased ABC activity in TAM. 
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Figure Legends 
 
Figure 1. Ontogeny and phenotype of TAM during ID8 tumor development. 
(A) Analysis of peritoneal macrophages (PM) by flow cytometry after intra-peritoneal (i.p.) 
injection of 106 ID8-Luc cells. PM were gated as; live, single cells (FSC-H versus FSC-W), 
CD45.2+, Lin- (NK1.1 Ly6G CD5 CD19), CD11b+, CD64+. LPM were subsequently gated as 
F4/80hi MHCII- (blue), intPM as F4/80int MHCIIint (orange) and SPM as F4/80- MHCIIhi (green). 
(B) Total numbers of LPM, intPM and SPM during tumor growth. (C) Shielded chimeras 
reconstituted with mixed bone marrow to analyze ontogeny of PM after engraftment with ID8-
Luc cells. Host mice (CD45.1) were placed in protective lead shield with only the hind legs 
exposed, before irradiation with 9 Gy. The following day, mice were reconstituted with a 
mixture of bone marrow cells from Ccr2-/- (CD45.2) and CD45.1/2 congenic mice, at a ratio of 
4:1. 5 weeks after reconstitution, mice were injected with ID8-Luc cells. A further 8 weeks after 
tumor inoculation, PM were collected for analysis. (D) Analysis of PM from chimeric mice by 
flow cytometry; CD45.1 and CD45.2 expression was analyzed on LPM (blue), intPM (orange) 
and SPM (green), as described above. (E) Proportion of chimerism was calculated relative to 
blood monocytes. (F,G) Fate mapping of Cx3cr1-expressing monocytes in ID8 tumor-bearing 
mice; Cx3cr1CreER:R26-tdRFP mice were inoculated with ID8-Luc cells, after 8 weeks 1 mg 
tamoxifen was administered by oral gavage and RFP expression was analyzed in PM subsets 
10 days later. RFP expression within LPM, intPM and SPM is shown. (H,I) PM were collected 
from naïve mice and at 5 or 21 days after tumor inoculation by flow cytometry. Total cellular 
mRNA was extracted and global gene expression profiles analyzed using microarrays. Gene 
ontology enrichment was perfomed on the differentially expressed genes (DEGs) between 
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naïve PM and TAM at (H) 5 and (I) 21 days, respectively. Graphs are represented as mean ± 
SEM. See also Figures S1 and S2. 
 
Figure 2. Increased membrane cholesterol efflux in TAM.  
(A,B) Peritoneal macrophages were isolated from naïve mice (Ctrl) or at 5 and 21 days after 
inoculation with ID8 cells. Cells were seeded in chambered plastic slides and stained with 
Cholera Toxin B (CTB; green) and TO-PRO-3 (blue). (A) Representative images for all three 
groups are shown, (B) quantification of corrected total cell fluorescence (CTCF). (C,D) BMDM 
were co-cultured with ID8 cells for the indicated time points prior to CTB staining, (C) 
representative images for BMDM alone (Ctrl) and 3 hours after ID8 co-culture and (D) 
quantification of CTCF. (E-H) BMDM were incubated with ID8-CM overnight, or Methyl-β-
cyclodextrin for 30 min, prior to CTB staining or di-4-ANEPPDHQ staining; (E) representative 
images for CTB staining in each condition and (F) quantification of CTCF. (G) Representative 
images of di-4-ANEPPDHQ staining and (H) quantification of relative changes in GP values 
(Owen et al., 2011). (I) Total cell cholesterol content was measured in BMDM with and without 
ID8-CM treatment, using the Amplex Red Cholesterol Assay kit. (J) BMDM from wild-type (WT) 
or Abca1-/- mice were loaded with 3H-labeled cholesterol and subsequently treated or not with 
ID8-CM in the presence of ApoA1, as an acceptor for cholesterol. 3H-Cholesterol was 
measured in the medium as a readout for cholesterol efflux. Graphs are represented as mean 
± SEM. 
 
Figure 3. Tumor cell-derived hyaluronic acid (HA) oligomers deplete lipid rafts in 
macrophages.  
(A) BMDM were co-cultured with live or paraformaldehyde-treated (fixed) ID8 cells, prior to 
CTB staining, quantification of CTCF is shown. (B) High and low molecular weight fractions of 
ID8-CM were prepared using Centricon filters with 100 kDa pores, each fraction was compared 
with unfractionated ID8-CM for effects on CTB staining. (C) BMDM were treated with ID8-CM 
with and without hyaluronidase (HAse) treatement prior to CTB staining and quantification. (D) 
BMDM were incubated with HA oligomers of increasing molecular weights before CTB staining 
and quantification, ID8-CM was used as a positive control. Graphs are represented as mean 
± SEM. 
  
 
Figure 4. Cholesterol efflux promotes IL-4 mediated macrophage reprogramming.  
(A,B) BMDM were treated with or without ID8-CM before stimulation with increasing 
concentrations of IL-4 or IFN for 8 hours. (A) Quantitative PCR (qPCR) analysis of IL-4 
induced gene expression; Arg1, Chi3l3, Mrc1, Retnla and (B) IFN-induced expression of Nos2 
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and Il12b. (C) BMDM were treated with different cholesterol depleting agents; 9-cis-retenoic 
acid (9cRA), high-density lipoprotein (HDL) or apolipoprotein A1 (ApoA1), as well as ID8-CM; 
lipid raft density was subsequently measured by CTB staining, quantification of CTCF is 
shown. (D) IL-4 (20 ng/ml) induced Arg1 and IFN (20 ng/ml) induced Nos2 expression in 
BMDM treated with 9cRA, HDL or ApoA1, compared to ID8-CM. (E) BMDM from Abca1/g1f/f 
and Abca1/g1Lyz2 mice were incubated with ID8-CM, 9cRA, HDL or ApoA1 and lipid raft 
density was measure by CTB staining, quantification of CTCF is shown. (F) IL-4 induced Arg1 
and IFN induced Nos2 expression in BMDM from Abca1/g1f/f and Abca1/g1Lyz2 mice with and 
without ID8-CM treatment. Graphs are represented as mean ± SEM. See also Figure S3. 
  
 
Figure 5. Tumor-induced reprogramming  is STAT6 and PI3K dependent.  
(A-F) BMDM were treated with or without ID8-CM overnight before stimulation with either IL-4 
or IFN for 20 min. Cells were then fixed and stained for p-STAT6, p-STAT1 or p-Akt and 
analyzed by confocal microscopy; representative micrographs for (A) p-STAT6, (B) p-STAT1 
and (C) p-Akt staining are shown (green), nuclei are counterstained with TO-PRO-3 (blue). (D-
F) Quantification of CTCF for (D) p-STAT6, (E) p-STAT1 and (F) p-Akt  (NS – non stimulated). 
(G-I) BMDM were incubated with or without ID8-CM in the presence or absence of the PI3K 
inhibitor LY294002 (1.25 µM); (G) Quantification of p-Akt staining by confocal microscopy and 
(H-I) qPCR analysis of IL-4-induced Arg1 and Chi3l3 expression. (J-K) BMDM were incubated 
overnight with ID8-CM, 9cRA, HDL or ApoA1 before stimulation with IL-4 for 20 min; 
quantification of (J) p-STAT6 and (K) p-Akt by confocal microscopy. (L-M) BMDM from 
Abca1/g1f/f and Abca1/g1Lyz2 mice were treated with ID8-CM before stimulation with IL-4 and 
quantification of (L) p-STAT6 and (M) p-Akt by confocal micrscopy. (N-O) BMDM treated with 
ID8-CM in the presence or absence of Rapamycin (Rapa) or Torin at the indicated 
concentrations; (N) quantification of p-Akt by confocal micrscopy and (O) western blot analysis 
of Ser473 and Thr308 Akt phosphorylation (pAkt(Ser) and pAkt(Thr), respectively) in 
Rapamycin (R) and Torin (T) treated BMDM with and without ID8-CM treatment. Graphs are 
represented as mean ± SEM. See also Figure S4. 
 
Figure 6. IL-4 induced STAT6 and PI3K signaling in TAM drives tumor progression in 
vivo.  
(A) Generation of specific gene signatures for Tim4+ and Tim4- F4/80hi PM and F4/80lo CCR2+ 
monocytes (MN) using GeneSign (BubbleGUM) cell-specific signatures were assessed for 
enrichment using BubbleMap (Spinelli et al., 2015), based on the GSEA algorithm in pairwise 
comparisons of Tim4+ PM from naïve mice or ID8 tumor-bearing mice at different time points. 
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The bubble area is proportional to the absolute value of the normalised enrichment score 
(NES). The color intensity indicates the false-discovery rate (FDR), modified for multiple 
testing. The size and intensity of color increases with the enrichment of the gene signature 
from the matching cell population; the Tim4+ gene signature is enriched in naïve cells (red), 
whereas the Tim4- and MN gene signatures are enriched in TAM (blue). (B) Leading edges 
(LEs) of the MN gene signature enrichment at different time points (highlighted by colored 
boxes) were extracted and plotted in a Venn diagram. Ingenuity Pathway Analysis (IPA) was 
performed on the 173 common LEs, showing IL4 as the top upstream regulator. (C) ID8-Luc 
cells were injected i.p. and mice treated with either IL4R blocking antibody (anti-IL4R) or an 
isotype control antbody (Iso-ctrl) after 2 weeks; tumor growth was assessed at 4 weeks by ex 
vivo luciferase assay on peritoneal cells. (D-E) Cohorts of chimeric mice receiving either wild-
type (WT), (D) Stat6-/- or (E) Pik3cd-/- bone marrow cells were injected with ID8-Luc cells and 
tumor growth assessed after 6 weeks. (F,G) TAM were isolated from Pik3cd-/- chimeric mice 
and WT controls after 6 weeks of tumor growth by flow cytometry. Microarray analysis was 
performed to assess geneset enrichment using GSEA. (F) Positive enrichment of the naïve 
PM gene signature in Pik3cd-/- TAM compared to WT cells and (G) negative enrichment of the 
IL-4 pathway signature of TAM (from B) in Pik3cd-/- cells. ES plots are shown on the left and 
the 25 most enriched genes on the right. NES, normalised enrichment score; FDR, false 
discovery rate. (H) Abca1/g1f/f and Abca1/g1Lyz2 mice were injected with ID8-Luc cells and 
tumor growth assessed after 6 weeks. (I) GSEA with TAM isolated from Abca1/g1f/f and 
Abca1/g1Lyz2 mice showing negative enrichment of the TAM associated IL4 pathway in 
Abca1/g1Lyz2 mice. Graphs are represented as mean ± SEM. See also Figure S5. 
 
 
STAR Methods 
 
Key Resources Table 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
anti-Nos2 (M-19) Santa Cruz sc-650 
anti-Arg1 (N-20) Santa Cruz sc-18351 
HRP-conjugated anti-Rabbit immunoglobulins DAKO P044801-2 
HRP-conjugated anti-Mouse immunoglobulins DAKO P026002-2 
anti-β-Actin (AC-74) Sigma A5316 
anti-Akt (40D4) Cell Signaling 2920 
anti-pSer473-Akt (D9E) Cell Signaling 4060 
anti-pThr308-Akt (D25E6) Cell Signaling 13038 
anti-STAT1 Cell Signaling 9172 
anti-pTyr701-STAT1 Cell Signaling 9171 
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anti-STAT6 (M-20) Santa Cruz sc-981 
anti-pTyr641-STAT6  Cell Signaling 9361 
anti-PIP3 Cell Signaling  
Anti-CD124 Novus Biologicals NBP1-00884 
anti-CD11b (M1/70) BD Biosciences,  563553 
anti-CD44 (IM7) BD Biosciences, 
eBioscience, BioLegend, 
and Life Technologies. 
 
anti-CD45.1 (A20) BD Biosciences, 
eBioscience, BioLegend, 
and Life Technologies. 
553775 
anti-NK1.1 (PK136) BioLegend 108724 
anti- Ly6G (1A8) BD Biosciences 560600 
anti- CD5 (53-7.3) BD Biosciences 563194 
anti-CD19 (1D3) BD Biosciences 565076 
anti-CD64 (X54-5/7.1 BioLegend 139311 
anti-Ly6C (AL-21) BD Biosciences 553104 
anti-MHCII (M5/114) eBioscience 56-5321-82 
anti-F4/80 (BM8) BioLegend 123141 
anti-Lyve-1 (ALY7) eBioscience 53-0443-82 
anti-rabbit-Alexa488 Invitrogen A-10040 
Chemicals, Peptides, and Recombinant Proteins 
LY294002 R&D Systems 1130 
Rapamycin Merck 553211 
Hyaluronic acid Lifecore Biomedical HA15M-1 
Hyaluronidase Sigma H3506 
Torin Sigma 475991 
Methyl-β-cyclodextrin Sigma C4555 
High-density lipoprotein Sigma L8039 
9-cis-retenoic acid Sigma R4643 
Cholesterol-methyl-β-cyclodextrin Sigma C4951 
Proteinase inhibitor cocktail Sigma P8340 
Xylazine  Sigma 23076-35-9 
PNPP Sigma 333338-18-4 
β-glycerophosphate  Sigma G9422 
DTT Sigma 43819 
Apolipoprotein A1 Sigma A0722 
Recombinant mouse IL4 Peprotech 214-14 
Recombinant mouse IFNγ Peprotech 315-05 
Recombinant mouse M-CSF Peprotech 315-02 
Recombinant mouse IL13 Peprotech 210-13 
Vybrant Alexa Fluor 488 Lipid Raft Labelling Kit ThermoFisher Scientific V34403 
TRIzol ThermoFisher Scientific 15596018 
di-4-ANEPPDHQ ThermoFisher Scientific D36802 
TO-PRO-3 ThermoFisher Scientific T3605 
SYBR Green PCR Master Mix ThermoFisher Scientific 4312704 
IL4Rα neutralizing antibody BD Biosciences 552508 
Critical Commercial Assays 
Superscript IV Reverse Transcriptase Thermo Fisher Sientific 18090050 
Amplex Red Cholesterol Assay kit ThermoFisher Scientific A12216 
   
Deposited Data 
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GSE126079 This paper https://www.ncbi.
nlm.nih.gov/geo/q
uery/acc.cgi?acc
=GSE126079 
GSE126080 This paper https://www.ncbi.
nlm.nih.gov/geo/q
uery/acc.cgi?acc
=GSE126080 
GSE126098 This paper https://www.ncbi.
nlm.nih.gov/geo/q
uery/acc.cgi?acc
=GSE126098 
   
Experimental Models: Cell Lines 
Bone marrow derived macrophages This paper Hagemann et al., 
2008 
ID8-Luc ovarian surface epithelial cell line Prof. Frances Balkwill Barts Cancer 
Institute, London, 
UK 
   
Experimental Models: Organisms/Strains 
Mouse:  C57Bl/6 Charles River JAX 000664 
Mouse: Abca1tm1Jp Abcg1tm1Tall Jackson Laboratories stock number 
021067 
Mouse: Lyz2tm1(cre)Ifo Jackson Laboratories stock number 
004781 
Mouse: Stat6−/− Dr. Bernard Malissen CIML, Marseille, 
FR 
Mouse: Abca1−/− Prof. Miranda Van Eck Leiden University, 
NL 
Mouse: Cx3cr1+/eGFP Jackson Laboratories stock number 
005582 
Cx3cr1cre/ERT2 Dr. Stephan Jung Department of 
Immunology, The 
Weizmann 
Institute of 
Science, 
Rehovot, Israel. 
Mouse: Pik3cd-/- Prof. Martin Turner Babraham 
Institute, 
Cambridge, UK 
Oligonucleotides 
Arg1; F-CAGAAGAATGGAAGAGTCAG This paper N/A 
Arg1; R-CAGATATGCAGGGAGTCACC This paper N/A 
Chi3l3; F-TCACAGGTCTGGCAATTCTTCTG This paper N/A 
Chi3l3; R-TTTGTCCTTAGGAGGGCTTCCTC  This paper N/A 
Ciita; F-CTCAGCCTTAGGAGGGACTTG This paper N/A 
Ciita; R-GACCTGGATCGTCTCGTGCAG This paper N/A 
Cph; F-GGCAAATGCTGGACCAAACAC This paper N/A 
Cph; R-TTAGAGTTGTCCACAGTCGGAGATG This paper N/A 
Cxcl9; F-TCCTTTTGGGCATCATCTTC This paper N/A 
Cxcl9; R-TTCCCCCTCTTTTGCTTTTT This paper N/A 
Cxcl10; F-GGGCCATAGGGAAGCTTGAA This paper N/A 
Cxcl10; R-GGATTCAGACATCTCTGCTCATCA This paper N/A 
Il12b; F-GGAA GCACGGCAGCAGAATA This paper N/A 
Il12b; R-AACTTGAGGGAGAAGTAGGAATGG This paper N/A 
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Ccl2; F-GCCAGCTCTC TCTTCCTCCA This paper N/A 
Ccl2; R-CCCAGAAGCATGACAGGGAC This paper N/A 
Nos2; F-CCCTCCTGATCTTGTGTT GGA This paper N/A 
Nos2; R-CCACCCGAGCTCCTGGAAC This paper N/A 
Retnla; F-GTCCCAGTGCATATGGATGAGACCATAGA This paper N/A 
Retnla; R-ACCTCTTCACTCGAGGGACAGTTGGCAGC This paper N/A 
Software and Algorithms 
FIJI software Schindelin, J., et al. 2012 https://fiji.sc/ 
FlowJo cytometric analytical software Tree Star  
Gene Set Enrichment Analysis (GSEA) Broad Institute Subramanian et 
al., 2005 
Affymetrix Expression Console version 1.1 software Affymetrix  
Prism software Graphpad  
BioLayout Express3D  Theocharidis et 
al., 2009 
Other 
   
   
   
 
 
Materials 
The following materials were employed throughout the study: LY294002, Torin, Rapamycin 
(Merck); hyaluronic acid, hyaluronidase, methyl-β-cyclodextrin, apolipoprotein A1, high-
density lipoprotein, 9-cis-retenoic acid and cholesterol-methyl--cyclodextrin (Sigma); 
recombinant mouse IL-4, IFN and M-CSF (Peprotech); IL4R neutralizing antibody (BD 
Biosciences). 
 
Mice 
C57Bl/6 mice were obtained from Charles River. All transgenic mouse strains were 
backcrossed to a C57Bl/6 background. Abca1tm1Jp Abcg1tm1Tall (Abca1/g1f/f) and Lyz2tm1(cre)Ifo 
(Lyz2Cre) mice were obtained from Jackson Laboratories. Stat6−/− mice were kindly donated by 
Dr. Bernard Malissen (CIML, Marseille, FR), Abca1−/− mice by Prof. Miranda Van Eck (Leiden 
University, NL) and Pik3cd-/- mice by Prof. Martin Turner (Babraham Institute, Cambridge, UK). 
Generation of shielded chimeras was performed as previously described (Scott et al., 2016); 
briefly, CD45.1 congenic mice mice were anaesthetised with Ketamine (150 mg/kg) and 
Xylazine (10 mg/kg) and placed in 6 mm thick lead cylinders, exposing only the hind legs. With 
the peritoneal cavity protected, mice were irradiated with 9 Gy and reconstituted with 107 bone 
marrow cells from Ccr2-/- (CD45.2) and CD45.1/2 mice, at a ratio of 4:1. After 5 weeks, 
chimerism of blood leukocytes was assessed by flow cytometry. All mice were housed under 
specific pathogen‐free conditions and animal experimentation was conducted in strict 
accordance with good animal practice as defined by the French animal welfare bodies relative 
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to European Convention (EEC Directive 86/609) and approved by the Direction Départmentale 
des Services Vétérinaires des Bouches du Rhônes. 
 
Cell Culture  
Bone marrow derived macrophages (BMDM) were obtained as previously described 
(Hagemann et al., 2008); briefly, femurs and tibiae from mice aged 8 to 10 weeks were flushed 
and cells collected by centrifugation at 450 g for 5 min at 4°C. Cells were resuspended in 
DMEM supplemented with L-glutamine (2 mM), penicillin (100 U/ml)/streptomycin (100 g/ml) 
(Gibco), 10 % heat-inactivated FBS and 10 ng/ml recombinant mouse M-CSF (Peprotech) and 
cultured at a density of 106 cells/ml in non-tissue culture treated plastic dishes (BD 
Pharmingen) at 37°C and 5 % CO2. After 7 days, adherent cells were collected and 
resuspended in complete DMEM containing 10 ng/ml M-CSF. The ID8-Luc ovarian surface 
epithelial cell line was kindly provided by Prof. Frances Balkwill (Barts Cancer Institute, 
London, UK). To obtain ID8 cell-conditioned conditioned medium (ID8-CM); 13.75 x106 cells in 
25 ml were incubated for 72 hours in a 175 cm2 flasks in DMEM containing 4 % of FCS. Medium 
was filtered through a 22 M filter, aliquoted and stored at -80°C.  
 
Immunofluorescence and lipid raft staining 
BMDM were grown in Lab-Tek chambered slides (ThermoFisher Scientific) and fixed with 4 % 
PFA, permeabilised (0.1 % Triton-X100) and blocked in 5 % BSA with 10 mM glycine. The 
following primary antibodies were used for incubation during 90 minutes at 4°C; anti-pSTAT1, 
anti-pSTAT6, anti-pSer473-Akt, anti-pThr308-Akt, anti-PIP3 (Cell Signaling) or anti-IL4R 
(Novus biologicals). After washing, anti-rabbit-Alexa488 (Invitrogen) and TO-PRO-3 
(ThermoFisher Scientific) were added for 60 minutes. Lipid rafts were stained using the 
Vybrant Alexa Fluor 488 Lipid Raft Labelling Kit, following manufacturer’s instructions. Briefly, 
BMDM were grown and stimulated in Lab-Tek chambered slides. After washing with serum-
free DMEM, they were incubated for 10 minutes with Alexa488-conjugated cholera toxin 
subunit B (CTB) at 4°C, followed by cross-linking with an anti-CTB antibody for 15 minutes at 
4°C. Subsequently, the cells were fixed with 4 % Antigenfix (DiaPath) for 10 minutes on ice 
and nuclei were stained with TO-PRO-3. The di-4-ANEPPDHQ lipid raft staining protocol was 
adapted from the one described by Owen et al. (Owen et al., 2011). Briefly, culture medium 
was replaced with fresh, serum-free DMEM containing 2 l of di-4-ANEPPDHQ (5 M). Dishes 
were shaken to ensure good mixing. After 30 min incubation at 37 °C in a humidified 5 % CO2 
atmosphere, cells were fixed with 4 % PFA. Fluorescence was measured by confocal 
microscopy (Zeiss LSM780 or Leica SP5X) and analyzed with FIJI software. The corrected 
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total cell fluorescence (CTCF) was measured for each cell in at least 6 different fields of view 
per well. 
 
Cholesterol measurement 
Total cell cholesterol content was measured in BMDM using the Amplex Red Cholesterol 
Assay kit (ThermoFisher Scientific), according to the manufacturer’s instructions. 
 
Immunoblotting 
BMDM were lysed on ice in lysis buffer supplemented with proteinase inhibitor cocktail, PNPP, 
β-glycerophosphate and DTT. Separation by SDS-PAGE was followed by blotting on PVDF 
membrane. Blots were blocked with 5 % skimmed milk in TBS-0.05 %Tween20. The following 
primary antibodies were used; anti-Nos2, anti-Arg1 (Santa Cruz), anti-β-Actin (Sigma), anti-
Akt, anti-pSer473-Akt, anti-pTyr701-STAT1, anti-STAT1, anti-pTyr641-STAT6 (Cell Signaling) 
and anti-STAT6 (Santa Cruz). Primary antibodies were incubated overnight at 4°C and 
appropriate HRP-conjugated secondary antibodies (DAKO) for 1 hour at room temperature. 
Chemoluminescence was detected by Pierce ECL Western Blotting Substrate (Thermo 
Scientific).  
 
Gene expression analysis 
Total cellular RNA was extracted from BMDM using TRIzol and cDNA was synthesised with 
cDNA Synthesis Kit (Thermo Fisher Sientific) according to the manufacturer’s protocol. Gene 
expression was quantified using sequence specific primers in the presence of SYBR Green 
PCR Master Mix using an ABI 7900HT thermocycler (Applied Biosystems). Reactions were 
performed in duplicate or triplicate and Ct-values were normalised to the mean Ct-values of 
cyclophillin. Relative quantification of gene expression was calculated as 2ΔΔCt to controls. 
Primers used: Arg1; F-CAGAAGAATGGAAGAGTCAG, R-CAGATATGCAGGGAGTCACC. 
Chi3l3; F-TCACAGGTCTGGCAATTCTTCTG, R-TTTGTCCTTAGGAGGGCTTCCTC Cph; F-
GGCAAATGCTGGACCAAACAC, R-TTAGAGTTGTCCACAGTCGGAGATG. Il12b; F-GGAA 
GCACGGCAGCAGAATA, R-AACTTGAGGGAGAAGTAGGAATGG. Ccl2; F-GCCAGCTCTC 
TCTTCCTCCA, R-CCCAGAAGCATGACAGGGAC. Nos2; F-CCCTCCTGATCTTGTGTT 
GGA, R-CCACCCGAGCTCCTGGAAC. Retnla; F-GGTCCCAGTGCATATGGATGAGACCA 
TAGA, R-CACCTCTTCACTCGAGGGACAGTTGGCAGC. Cxcl9; F-TCCTTTTGGGCATCATCTTC, 
R-TTCCCCCTCTTTTGCTTTTT. Cxcl10; F-GGGCCATAGGGAAGCTTGAA, R-
GGATTCAGACATCTCTGCTCATCA. Ciita; F-CTCAGCCTTAGGAGGGACTTG, R-
GACCTGGATCGTCTCGTGCAG. 
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Ovarian cancer model  
One million ID8 cells were injected intraperitoneally in the different mouse strains using a 27G 
syringe. Mice were euthanised at the indicated times and peritoneal lavages were collected for 
cytometric analysis, ex vivo bioluminescence measurement and/or lipid raft staining. Briefly, 9 
ml of ice cold PBS was injected intraperitoneally and after a careful massage to detach all the 
cells in the cavity, peritoneal fluid was collected through a 23G syringe. Tubes were weighed 
to determine the recovered lavage volume and the cell density was assessed using a Casy 
cell counter (Innovatis). Cells were centrifugated and resuspended in 1 ml cold PBS. One 
million cells from each peritoneal lavage were stained for flow cytometry. 50 l of the 1 ml cell 
suspension obtained from peritoneal lavage was used for luciferase activity measurements. 
Cells were plated in a white 96-well plate and 50 l luciferin was added to each well, 
Luminescence [photons/s] was measured for each well using the Mithras Microplate Reader 
(Berthold Technologies).   
 
Flow Cytometry 
Peritoneal lavage cells underwent a short NH4Cl red blood cell lysis and were incubated at 4°C 
for 10 min with the 2.4.G2 antibody to block Fc receptors. The cells were stained with the 
indicated antibodies for 30 min at 4°C. Dead cells were gated out using SYTOX Blue dead cell 
stain (Life Technlogies). After cell-surface staining, cells were fixed. Analysis was performed 
using an LSR-II flow cytometer or sorted using an Aria III cell sorter (both BD Biosciences) and 
data analysis was conducted with the FlowJo cytometric analytical software (Tree Star). Anti-
CD11b (M1/70), anti-CD44 (IM7), anti-CD45.1 (A20), anti-CD45.2 (104), NK1.1, Ly6G, anti-
CD5 (53-7.3), anti-CD19 (1D3), anti-CD64, anti-Ly6C (AL-21), anti-F4/80 and anti-MHCII 
(M5/114) were purchased from BD Biosciences, eBioscience, BioLegend, and Life 
Technologies.   
 
Microarray Analysis 
RNA samples were hybridised on Affymetrix Mouse 430 2.0 or MoGene 1.0 st chips. Samples 
were processed as follows: The biotinylated cRNAs were prepared according to a double 
amplification protocol using MessageAmp™ II aRNA Amplification Kit (Ambion). The images 
of the chips were generated with Affymetrix software AGCC version 3.2. The expression data 
was then extracted with the Affymetrix Expression Console version 1.1 software using the RMA 
(log2 scale) and MAS5 (linear scale) algorithms. Gene Set Enrichment Analysis (GSEA, Broad 
Institute) (Subramanian et al., 2005) was used to examine differentially expressed genes 
(DEGs). The output of GSEA is an enrichment plot (ES), a normalised enrichment score (NES) 
which accounts for the size of the gene set being tested, a p-value, and an estimated False 
Discovery rate (FDR). We computed P values using 1,000 permutations for each gene set and 
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corrected them with the false-discovery rate (FDR) method. When several probe sets were 
present for a gene, the mean of the probe set was used. Cell-specific gene sets were 
generated by performing pairwise comparisons between DEGs from different populations, 
applying a 1.5 FC threshold and a p value of 0.05, using the Minimal 
(pairwise[Mean(test)/Mean(ref)]) method. Sample correlation  analysis was performed based 
on Pearson’s correlation coefficients using BioLayout Express3D (Theocharidis et al., 2009). 
GO enrichment analysis was applied using the Cytoscape plug‐in BiNGO (v2.44) (Maere et 
al., 2005) with FDR q‐value threshold of 0.05 as default. The Cytoscape plugins Enrichment 
Map (v1.1) (Merico et al., 2010) and Word Cloud (Oesper et al., 2011) were used to visualize 
the GO networks. Accession numbers for datasets are; GSE126079, GSE126080, 
GSE126098. 
 
Statistical Analysis 
Graphs were made and statistical analysis was performed using Prism software (Graphpad). 
All quantitative data are presented as mean ± SEM. Statistical significance was calculated 
using Student´s t-test, Wilcoxon-Mann-Whitney test, Chi-square test for contingency tables or 
One-Way ANOVA. P values <0.05 were considered as significant.   
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Supplemental Information 
Figure S1. CCR2-dependency of peritoneal macrophage subsets and TAM – related to 
Figure 1.  
Wild-type (WT) and Ccr2-/- mice were injected with 106 ID8-Luc cells i.p. After 8 weeks, mice 
were euthanized and ascites was harvested by peritoneal lavage and analyzed by flow 
cytometry. (A) Peritoneal macrophages were gated as live cells; CD45.2+, Lin- (CD5, CD19, 
Ly6G, NK1.1), CD11b+ and CD64+. Large peritoneal macrophages (LPM) were subsequently 
gated as F4/80hi MHCII-, intermediate peritoneal macrophages (intPM) as F4/80+ MHCII+ and 
small peritoneal macrophages (SPM) as F4/80- MHCII+. (B) Total numbers of LPM, intPM and 
SPM in naïve and ID8-Luc injected mice were calculated. (C) Analysis of Cx3cr1 expression 
in LPM, intPM and SPM from Cx3cr1egfp/+ reporter mice bearing ID8 tumors. (D) Analysis of 
Lyve-1 expression in LPM, intPM and SPM from ID8-Luc injected mice by flow cytometry. 
Figure S2. Microarray analysis of TAM versus naïve PM – related to Figure 1. 
(A) Gating strategy for sorting of TAM by flow cytometry; bulk TAM were gated as live cells,
CD45.2+, CD11b+, Lin- (CD5, CD19, Ly6G, NK1.1), F4/80+ and CD64+. (B) Total RNA was
extracted from TAM sorted from ascites at 5 (D5), 12 (D12) and 21 days (D21) of tumour
growth and naive peritoneal macrophages (Ctrl). Gene expression was analyzed with MoGene
1.0st microarrays. RMA normalized data were filtered and analyzed for variations in gene
expression and hierarchical clustering, the heatmap represents the 1000 most variable genes
expressed. (C) Sample correlation analysis based on Pearson’s correlation coefficients using
BioLayout Express3D. (D) Ingenuity Pathway Analysis (IPA) with DEGs between naive PM
(Ctrl) and TAM at day 21 (D21). (E-F) GSEA comparing TAM with naive PM using a compiled
cholesterol homeostasis geneset; (E) Heatmap representing significantly enriched genes in
TAM (D21), and (F) the enrichment plot indicating normalized enrichment score (NES) and
false discovery rate (FDR).
Figure S3. ID8 cells promote M2-polarisation of macrophages – related to Figure 4. 
(A) BMDM were co-cultured with or without ID8 cells at a 1:1 ratio overnight, ID8 cells were
removed by washing before stimulation with IL-4 or IFNg for 8 hours and analysis of Arg1 and
Nos2 expression by qPCR. (B) BMDM were treated with or without ID8-CM before stimulation
with IL-13 (20 ng/ml) for 8 hours and Arg1 expression analysed by qPCR. (C) BMDM were
stimulated with IL-4 after treatment with fractions of ID8-CM obtained after filtering with cut-
offs at 3, 10, 30 and 100 kDa, Arg1 expression was analysed by qPCR after 8 hours. (D-E)
BMDM treated with ID8-CM were incubated with and without cholesterol-methyl-b-cyclodextrin
Supplemental Text and Figures
(Chl) to replenish membrane cholesterol before stimulation with IL-4 of IFNg; Arg1 and Nos2 
expression were analysed by qPCR or western blotting after 8 hours. (F) BMDM were treated 
with or without ID8-CM before stimulation with IFNg for 8 hours. Cxcl9, Cxcl10 and Ciita gene 
expression was determined by qPCR. Data is represented as mean ± SEM of 3 independent 
experiments. 
Figure S4. Tumor-induced macrophage reprogramming is STAT6 and PI3K-dependent 
– related to Figure 5.
(A,B) BMDM were treated with or without ID8-CM in the absence of cytokine stimulation. After
fixation and permeabilization, they were stained for IL-4R and its subcellular location was
imaged by confocal microscopy; (A) representative images are shown, (B) receptor clustering
was quantified by plotting the mean aggregate size defined as areas larger than 0.2µm² with
a mean fluorescence intensity higher than twice the background signal. (C-E) BMDM were
treated with or without (C) ID8-CM either alone and with subsequent (D) IFNg or (E) IL-4
stimulation; pAKT (ser473), pSTAT1 (Tyr701) and pSTAT6 (Tyr641) were measured by
Western Blot at the indicated time points in minutes. Total Akt, STAT1, STAT6 or Actin were
used as loading controls. Representative blots from at least 3 independent experiments are
shown. (F) BMDM from wild-type (WT) and Stat6-/- mice were treated with and without ID8-CM
before stimulation with IL-4 and Arg1 expression was measured after 8 hours by western
blotting. (G) BMDM were treated with and without ID8-CM before stimulation with IL-4 and
accumulation PIP3 was measured by confocal microscopy. (H) BMDM were incubated with or
without ID8-CM in the presence or absence of the PI3K inhibitor LY294002 (1.25 µM) before
stimulation with IL-4 or IFNg; Arg1, Retnla, Chi3l3 and Nos2 expression were measured by
western blotting after 8 hours. (I) BMDM were stimulated with IL-4 after treatment with fractions
of ID8-CM obtained after filtering with cut-off at 100 kDa followed by quantification of p-STAT6
and p-Akt by confocal microscopy. (J) BMDM were incubated with ID8-CM with and without
HAse treatment before stimulation with IL-4, p-STAT6 and p-Akt was subsequently measured
by confocal microscopy.
Figure S5. IL-4 signaling and TAM polarization in vivo – related to Figure 6. 
(A) Gating strategy for sorting of monocytes (MN), Tim4+ and Tim4- PM by flow cytometry. (B)
Analysis of Tim4+ and Tim4- PM in Ccr2-/- mice. (C) Reduced expression of TAM marker genes
in bulk TAM from Pik3cd-/- chimeras compared to wild-type (WT) mice at 21 days (D21). (D)
GSEA using a tumoricidal gene signature (GSE26912) in naïve PM versus TAM after 21 days
(D21). (E) GSEA using the most enriched genes in naïve PM from (D) as a geneset in TAM
from WT versus Pik3cd-/- mice and Abca1/g1f/f versus Abca1/g1DLyz2 mice; enrichment plots are
shown on the left and the 25 most enriched genes on the right. Normalized enrichment score 
(NES) and false discovery rate (FDR), are indicated. (F) Heatmap showing expression of IL-4 
responsive genes in TAM from wild-type (WT) and Stat6-/- mice analysed by high-density 
quantitative PCR array. 
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